Topics

AstraZeneca's Imfinzi gets orphan drug designation from FDA

05:07 EDT 12 Jul 2019 | Pharmafile

AstraZeneca’s cancer immunotherapy Imfinzi has been granted orphan drug status as a treatment for small cell lung cancer (SCLC).

The FDA has granted Imfinzi (Durvalumab) an Orphan Drug Designation (ODD) as a treatment for SCLC which accounts for around 15% of all lung cancer diagnoses.

SCLC is the most aggressive form of lung cancer with only 6% of patients living for more than 5 years. The FDA grants ODDs to drugs which treat diseases which affect fewer than 200,000 people in the United States.

read more

Original Article: AstraZeneca's Imfinzi gets orphan drug designation from FDA

NEXT ARTICLE

More From BioPortfolio on "AstraZeneca's Imfinzi gets orphan drug designation from FDA"

Quick Search

Relevant Topics

The Top 100 Pharmaceutical Companies
Top 10 biotech and pharmaceutical companies worldwide based on market value in 2015 2015 ranking of the global top 10 biotech and pharmaceutical companies based on revenue (in billion U.S. dollars) Johnson & Johnson, U.S. 74...

Cancer Disease
Cancer is not just one disease but many diseases. There are more than 100 different types of cancer. Most cancers are named for the organ or type of cell in which they start - for example, cancer that begins in the colon is called colon cancer; cancer th...

Biological Therapy
Biological therapy involves the use of living organisms, substances derived from living organisms, or laboratory-produced versions of such substances to treat disease. Some biological therapies for cancer use vaccines or bacteria to stimulate the body&rs...